Screener
Cogent Biosciences, Inc. COGT Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:21 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-205170
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $903,006 | $937,607 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $13,744 | $9,504 |
| Accrued expenses and other current liabilities | 42,854 | 52,902 |
| Operating lease liabilities | 1,383 | 1,547 |
| Total current liabilities | 57,981 | 63,953 |
| Convertible senior notes, net | 223,173 | 222,895 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Cogent Biosciences, Inc.'s accounts payable?
- Cogent Biosciences, Inc. (COGT) reported accounts payable of $13.74M in Q1 2026.
- How has Cogent Biosciences, Inc.'s accounts payable changed year-over-year?
- Cogent Biosciences, Inc.'s accounts payable decreased by 2.9% year-over-year, from $14.15M to $13.74M.
- What is the long-term trend for Cogent Biosciences, Inc.'s accounts payable?
- Over 5 years (2020 to 2025), Cogent Biosciences, Inc.'s accounts payable has grown at a 67.0% compound annual growth rate (CAGR), from $732K to $9.5M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Cogent Biosciences, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude